IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice

Julian M. W. Quinn, Natalie A. Sims, Hasnawati Saleh, Danijela Mirosa, Keith Thompson, Stelios Bouralexis, Emma C. Walker, T. John Martin, Matthew T. Gillespie

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

IL-23 stimulates the differentiation and function of the Th17 subset of CD4(+) T cells and plays a critical role in chronic inflammation. The IL-23 receptor-encoding gene is also an inflammatory disease susceptibility gene. IL-23 shares a common subunit with IL-12, a T cell-dependent osteoclast formation inhibitor, and we found that IL-23 also dose-dependently inhibited osteoclastogenesis in a CD4(+) T lymphocyte-dependent manner. When sufficiently enriched, gamma delta T cells also mediated IL-23 inhibition. Like IL-12, IL-23 acted synergistically with IL-18 to block osteoclastogenesis but, unlike IL-12, IL-23 action depended on T cell GM-CSF production. IL-23 did not mediate IL-12 action although IL-12 induced its expression. Male mice lacking IL-23 (IL-23p19(-/-)) had similar to 30% lower bone mineral density and tibial trabecular bone mass (bone volume (BV)/total volume (TV)) than wild-type littermates at 12 wk and 40% lower BV/TV at 26 wk of age; male heterozygotes also had lower bone mass. Female IL-23p19(-/-) mice also had reduced BV/TV. IL-23p19(-/-) mice had no detectable osteoclast defect in trabecular bone but IL-23p19(-/-) had thinner growth plate hypertrophic and primary spongiosa zones (and, in females, less cartilage remnants) compared with wild type. This suggests increased osteoclast action at and below the growth plate, leading to reduced amounts of mature trabecular bone. Thus, IL-23 inhibits osteoclast formation indirectly via T cells in vitro. Under nonpathological conditions (unlike inflammatory conditions), IL-23 favors higher bone mass in long bones by limiting resorption of immature bone forming below the growth plate.

Original languageEnglish
Pages (from-to)5720-5729
Number of pages10
JournalThe Journal of Immunology
Volume181
Issue number8
Publication statusPublished - 15 Oct 2008

Keywords

  • colony-stimulating factor
  • formation in-vitro
  • T-cell-activation
  • hypersensitivity responses
  • factor gene
  • GM-CSF
  • cytokine
  • receptor
  • osteoprotegerin
  • IL-12

Cite this

Quinn, J. M. W., Sims, N. A., Saleh, H., Mirosa, D., Thompson, K., Bouralexis, S., ... Gillespie, M. T. (2008). IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. The Journal of Immunology, 181(8), 5720-5729.

IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. / Quinn, Julian M. W. ; Sims, Natalie A.; Saleh, Hasnawati; Mirosa, Danijela; Thompson, Keith; Bouralexis, Stelios; Walker, Emma C.; Martin, T. John; Gillespie, Matthew T.

In: The Journal of Immunology, Vol. 181, No. 8, 15.10.2008, p. 5720-5729.

Research output: Contribution to journalArticle

Quinn, JMW, Sims, NA, Saleh, H, Mirosa, D, Thompson, K, Bouralexis, S, Walker, EC, Martin, TJ & Gillespie, MT 2008, 'IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice', The Journal of Immunology, vol. 181, no. 8, pp. 5720-5729.
Quinn JMW, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. The Journal of Immunology. 2008 Oct 15;181(8):5720-5729.
Quinn, Julian M. W. ; Sims, Natalie A. ; Saleh, Hasnawati ; Mirosa, Danijela ; Thompson, Keith ; Bouralexis, Stelios ; Walker, Emma C. ; Martin, T. John ; Gillespie, Matthew T. / IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. In: The Journal of Immunology. 2008 ; Vol. 181, No. 8. pp. 5720-5729.
@article{f4f76ca5afba4f3ea47eee22c4d1b398,
title = "IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice",
abstract = "IL-23 stimulates the differentiation and function of the Th17 subset of CD4(+) T cells and plays a critical role in chronic inflammation. The IL-23 receptor-encoding gene is also an inflammatory disease susceptibility gene. IL-23 shares a common subunit with IL-12, a T cell-dependent osteoclast formation inhibitor, and we found that IL-23 also dose-dependently inhibited osteoclastogenesis in a CD4(+) T lymphocyte-dependent manner. When sufficiently enriched, gamma delta T cells also mediated IL-23 inhibition. Like IL-12, IL-23 acted synergistically with IL-18 to block osteoclastogenesis but, unlike IL-12, IL-23 action depended on T cell GM-CSF production. IL-23 did not mediate IL-12 action although IL-12 induced its expression. Male mice lacking IL-23 (IL-23p19(-/-)) had similar to 30{\%} lower bone mineral density and tibial trabecular bone mass (bone volume (BV)/total volume (TV)) than wild-type littermates at 12 wk and 40{\%} lower BV/TV at 26 wk of age; male heterozygotes also had lower bone mass. Female IL-23p19(-/-) mice also had reduced BV/TV. IL-23p19(-/-) mice had no detectable osteoclast defect in trabecular bone but IL-23p19(-/-) had thinner growth plate hypertrophic and primary spongiosa zones (and, in females, less cartilage remnants) compared with wild type. This suggests increased osteoclast action at and below the growth plate, leading to reduced amounts of mature trabecular bone. Thus, IL-23 inhibits osteoclast formation indirectly via T cells in vitro. Under nonpathological conditions (unlike inflammatory conditions), IL-23 favors higher bone mass in long bones by limiting resorption of immature bone forming below the growth plate.",
keywords = "colony-stimulating factor, formation in-vitro, T-cell-activation, hypersensitivity responses, factor gene, GM-CSF, cytokine, receptor, osteoprotegerin, IL-12",
author = "Quinn, {Julian M. W.} and Sims, {Natalie A.} and Hasnawati Saleh and Danijela Mirosa and Keith Thompson and Stelios Bouralexis and Walker, {Emma C.} and Martin, {T. John} and Gillespie, {Matthew T.}",
year = "2008",
month = "10",
day = "15",
language = "English",
volume = "181",
pages = "5720--5729",
journal = "The Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice

AU - Quinn, Julian M. W.

AU - Sims, Natalie A.

AU - Saleh, Hasnawati

AU - Mirosa, Danijela

AU - Thompson, Keith

AU - Bouralexis, Stelios

AU - Walker, Emma C.

AU - Martin, T. John

AU - Gillespie, Matthew T.

PY - 2008/10/15

Y1 - 2008/10/15

N2 - IL-23 stimulates the differentiation and function of the Th17 subset of CD4(+) T cells and plays a critical role in chronic inflammation. The IL-23 receptor-encoding gene is also an inflammatory disease susceptibility gene. IL-23 shares a common subunit with IL-12, a T cell-dependent osteoclast formation inhibitor, and we found that IL-23 also dose-dependently inhibited osteoclastogenesis in a CD4(+) T lymphocyte-dependent manner. When sufficiently enriched, gamma delta T cells also mediated IL-23 inhibition. Like IL-12, IL-23 acted synergistically with IL-18 to block osteoclastogenesis but, unlike IL-12, IL-23 action depended on T cell GM-CSF production. IL-23 did not mediate IL-12 action although IL-12 induced its expression. Male mice lacking IL-23 (IL-23p19(-/-)) had similar to 30% lower bone mineral density and tibial trabecular bone mass (bone volume (BV)/total volume (TV)) than wild-type littermates at 12 wk and 40% lower BV/TV at 26 wk of age; male heterozygotes also had lower bone mass. Female IL-23p19(-/-) mice also had reduced BV/TV. IL-23p19(-/-) mice had no detectable osteoclast defect in trabecular bone but IL-23p19(-/-) had thinner growth plate hypertrophic and primary spongiosa zones (and, in females, less cartilage remnants) compared with wild type. This suggests increased osteoclast action at and below the growth plate, leading to reduced amounts of mature trabecular bone. Thus, IL-23 inhibits osteoclast formation indirectly via T cells in vitro. Under nonpathological conditions (unlike inflammatory conditions), IL-23 favors higher bone mass in long bones by limiting resorption of immature bone forming below the growth plate.

AB - IL-23 stimulates the differentiation and function of the Th17 subset of CD4(+) T cells and plays a critical role in chronic inflammation. The IL-23 receptor-encoding gene is also an inflammatory disease susceptibility gene. IL-23 shares a common subunit with IL-12, a T cell-dependent osteoclast formation inhibitor, and we found that IL-23 also dose-dependently inhibited osteoclastogenesis in a CD4(+) T lymphocyte-dependent manner. When sufficiently enriched, gamma delta T cells also mediated IL-23 inhibition. Like IL-12, IL-23 acted synergistically with IL-18 to block osteoclastogenesis but, unlike IL-12, IL-23 action depended on T cell GM-CSF production. IL-23 did not mediate IL-12 action although IL-12 induced its expression. Male mice lacking IL-23 (IL-23p19(-/-)) had similar to 30% lower bone mineral density and tibial trabecular bone mass (bone volume (BV)/total volume (TV)) than wild-type littermates at 12 wk and 40% lower BV/TV at 26 wk of age; male heterozygotes also had lower bone mass. Female IL-23p19(-/-) mice also had reduced BV/TV. IL-23p19(-/-) mice had no detectable osteoclast defect in trabecular bone but IL-23p19(-/-) had thinner growth plate hypertrophic and primary spongiosa zones (and, in females, less cartilage remnants) compared with wild type. This suggests increased osteoclast action at and below the growth plate, leading to reduced amounts of mature trabecular bone. Thus, IL-23 inhibits osteoclast formation indirectly via T cells in vitro. Under nonpathological conditions (unlike inflammatory conditions), IL-23 favors higher bone mass in long bones by limiting resorption of immature bone forming below the growth plate.

KW - colony-stimulating factor

KW - formation in-vitro

KW - T-cell-activation

KW - hypersensitivity responses

KW - factor gene

KW - GM-CSF

KW - cytokine

KW - receptor

KW - osteoprotegerin

KW - IL-12

M3 - Article

VL - 181

SP - 5720

EP - 5729

JO - The Journal of Immunology

JF - The Journal of Immunology

SN - 0022-1767

IS - 8

ER -